BDBM50306682 US10370379, Crizotinib (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine CHEMBL601719 US11059827, Compound Crizotinib US9199944, Crizotinib PF-2341066 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine US10543199, Compound Crizotinib US9126941, PF-2341066 US11517561, Compound Crizotinib CRIZOTINIB 3-(2,6-dichloro-3-fluorobenzyloxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine US10780082, Compound Crizotinib US9226923, Crizotinib
- Lim, JW; Kim, SK; Choi, SY; Kim, DH; Gadhe, CG; Lee, HN; Kim, HJ; Kim, J; Cho, SJ; Hwang, H; Seong, J; Jeong, KS; Lee, JY; Lim, SM; Lee, JW; Pae, AN Identification of crizotinib derivatives as potent SHIP2 inhibitors for the treatment of Alzheimer's disease. Eur J Med Chem 157: 405-422 (2018)
- Huang, Q; Johnson, TW; Bailey, S; Brooun, A; Bunker, KD; Burke, BJ; Collins, MR; Cook, AS; Cui, JJ; Dack, KN; Deal, JG; Deng, YL; Dinh, D; Engstrom, LD; He, M; Hoffman, J; Hoffman, RL; Johnson, PS; Kania, RS; Lam, H; Lam, JL; Le, PT; Li, Q; Lingardo, L; Liu, W; Lu, MW; McTigue, M; Palmer, CL; Richardson, PF; Sach, NW; Shen, H; Smeal, T; Smith, GL; Stewart, AE; Timofeevski, S; Tsaparikos, K; Wang, H; Zhu, H; Zhu, J; Zou, HY; Edwards, MP Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem 57: 1170-87 (2014)
- Liu, X; Zhang, L; Wan, H; Zhu, Z; Jin, J; Qin, Y; Mao, W; Yan, K; Fang, D; Jiang, W; Hu, L; Chen, J; Chen, K; Chen, S; Li, J; Zhao, S; Zheng, S; Zhang, L; Ding, CZ Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations. Bioorg Med Chem Lett 66: (2022)
- Chen, W; Guo, X; Zhang, C; Ke, D; Zhang, G; Yu, Y Discovery of 2-aminopyridines bearing a pyridone moiety as potent ALK inhibitors to overcome the crizotinib-resistant mutants. Eur J Med Chem 183: (2019)
- Mathi, GR; Kang, CH; Lee, HK; Achary, R; Lee, HY; Lee, JY; Ha, JD; Ahn, S; Park, CH; Lee, CO; Hwang, JY; Yun, CS; Jung, HJ; Cho, SY; Kim, HR; Kim, P Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. Eur J Med Chem 126: 536-549 (2017)
- Wang, Y; Chen, S; Hu, G; Wang, J; Gou, W; Zuo, D; Gu, Y; Gong, P; Zhai, X Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. Eur J Med Chem 143: 123-136 (2018)
- Liu, S; Jiang, Y; Yan, R; Li, Z; Wan, S; Zhang, T; Wu, X; Hou, J; Zhu, Z; Tian, Y; Zhang, J Design, synthesis and biological evaluations of 2-amino-4-(1-piperidine) pyridine derivatives as novel anti crizotinib-resistant ALK/ROS1 dual inhibitors. Eur J Med Chem 179: 358-375 (2019)
- Johnson, TW; Gallego, RA; Brooun, A; Gehlhaar, D; McTigue, M Reviving B-Factors: Retrospective Normalized B-Factor Analysis of c-ros Oncogene 1 Receptor Tyrosine Kinase and Anaplastic Lymphoma Kinase L1196M with Crizotinib and Lorlatinib. ACS Med Chem Lett 9: 878-883 (2018)
- Cui, JJ; Tran-Dubé, M; Shen, H; Nambu, M; Kung, PP; Pairish, M; Jia, L; Meng, J; Funk, L; Botrous, I; McTigue, M; Grodsky, N; Ryan, K; Padrique, E; Alton, G; Timofeevski, S; Yamazaki, S; Li, Q; Zou, H; Christensen, J; Mroczkowski, B; Bender, S; Kania, RS; Edwards, MP Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54: 6342-63 (2011)